CN117285514A — Hiv衣壳抑制剂的固体形式
Assigned to Gilead Sciences Inc · Expires 2023-12-26 · 2y expired
What this patent protects
本公开涉及化合物N‑((S)‑1‑(3‑(4‑氯‑3‑(甲基磺酰胺基)‑1‑(2,2,2‑三氟乙基)‑1H‑吲唑‑7‑基)‑6‑(3‑甲基‑3‑(甲磺酰基)丁‑1‑炔‑1‑基)吡啶‑2‑基)‑2‑(3,5‑二氟苯基)乙基)‑2‑((3bS,4aR)‑5,5‑二氟‑3‑(三氟甲基)‑3b,4,4a,5‑四氢‑1H‑环丙烯并[3,4]环戊二烯并[1,2‑c]吡唑‑1‑基)乙酰胺的药学上可接受的盐、共晶及其结晶形式，其可用于治疗逆转录病毒科病毒感染，包括由HIV病毒引起的感染。
USPTO Abstract
本公开涉及化合物N‑((S)‑1‑(3‑(4‑氯‑3‑(甲基磺酰胺基)‑1‑(2,2,2‑三氟乙基)‑1H‑吲唑‑7‑基)‑6‑(3‑甲基‑3‑(甲磺酰基)丁‑1‑炔‑1‑基)吡啶‑2‑基)‑2‑(3,5‑二氟苯基)乙基)‑2‑((3bS,4aR)‑5,5‑二氟‑3‑(三氟甲基)‑3b,4,4a,5‑四氢‑1H‑环丙烯并[3,4]环戊二烯并[1,2‑c]吡唑‑1‑基)乙酰胺的药学上可接受的盐、共晶及其结晶形式，其可用于治疗逆转录病毒科病毒感染，包括由HIV病毒引起的感染。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.